Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?
about
Current Research Therapeutic Strategies for Alzheimer's Disease TreatmentThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.Computational identification of potential multitarget treatments for ameliorating the adverse effects of amyloid-β on synaptic plasticityPET/SPECT imaging agents for neurodegenerative diseases.Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice.Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications.Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.Rescue of amyloid-Beta-induced inhibition of nicotinic acetylcholine receptors by a peptide homologous to the nicotine binding domain of the alpha 7 subtype.Systematic review of the relationship between amyloid-β levels and measures of transgenic mouse cognitive deficit in Alzheimer's disease.Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the futureAlzheimer's silent partner: cerebral amyloid angiopathy.Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.Immunotherapy for Alzheimer's disease: past, present and futureAmyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.Alzheimer's disease and immunotherapy: what is wrong with clinical trials?Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation.Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease.Monophosphoryl lipid A is an lipopolysaccharide-derived Toll-like receptor 4 agonist which may improve Alzheimer's disease pathology.Amino-Terminal β-Amyloid Antibody Blocks β-Amyloid-Mediated Inhibition of the High-Affinity Choline Transporter CHT.Calmodulin-like skin protein protects against spatial learning impairment in a mouse model of Alzheimer disease.Developing Cognitive Markers of Alzheimer's Disease for Primary Care: Implications for Behavioral and Global Prevention.Combining in vitro and in silico approaches to find new drugs targeting the pathological proteins related to the Alzheimer's disease.The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.Label-free imaging of amyloid plaques in Alzheimer's disease with stimulated Raman scattering microscopy
P2860
Q26765530-FF5B602F-2D94-485D-9EFB-F21C76D2AE51Q30668465-F72153BC-5C0C-4278-9D80-7DDE86DC6379Q33611723-37BCB5A3-86E1-43A1-BF83-34A338B4A87BQ34156602-C2B4288C-5EAD-44A9-9F51-80B25C435A03Q34240270-86FCAC66-34D4-4EDD-9543-4DB003522FE8Q34345602-123DB976-E046-4BC6-AD0C-AB9AF95444E5Q34584517-F6AD6732-8F43-40E9-917D-6AB954B37A33Q34872425-BD756F72-5C06-440E-9D0E-B8EC765ED3F8Q35137134-4E6033B8-C625-462D-9800-38955DDB2FDAQ36711795-F4BCABAE-1610-436B-A98B-705E77FDA1EEQ36899566-DB6B6E15-AE6D-4778-B14A-E20C4B22B7BCQ37031396-D590182F-B703-4DA4-A48E-6068F9142348Q37501943-F6A582C9-D117-4A38-BA9B-36518BE93161Q37656554-77F7E360-8FC0-47C2-916C-5B563C9BD34AQ37690944-37F6ED10-C96E-4421-9493-D24616B79E9FQ38140071-978D8BC7-7433-458B-80CA-0E6B7A9C0FCDQ38161675-468173C8-8E96-4E4B-8C90-F0FC0E64ED22Q38170047-7575DBDE-5F99-47F7-A23A-243284BE6474Q38184618-37B7671A-F199-4F88-90D6-93691A38D786Q38222750-7052E656-C3A9-44E2-8838-49BBEC539CB0Q38224958-BE65F7D7-1067-4DE1-88E2-EE80B90497EEQ38235780-CA7BB9C8-5E4F-4EDD-A04D-995FCD23DF9AQ38779044-59676976-CE95-489E-AC12-38BDED35AC54Q38912275-D76C4588-BB2D-4114-8A85-27CE2096D079Q38928927-0F00B170-9314-400D-B8D2-570BD017FD1DQ38966308-DB050C18-EA94-481E-947D-9D6D599D5317Q42689743-2B4DE96A-F6A3-4C68-BE5A-8F36FD31D7A4Q45733638-353444F0-D408-408B-BB81-CE7883DCAE99Q47113449-1CBD1F25-5AA3-49BA-89FD-CD6A08C82543Q47375015-7BF0FE52-2025-4F21-956A-D91A0240822CQ47391689-CB31E6EE-28E7-45A4-BEA4-D8941C644B47Q47396500-59278DF6-426A-4A84-8645-D4C737F73B29Q47567135-A70A7AD4-B0FA-406C-AC18-F443DD774B0CQ59136630-5B8E7A00-9350-4A9F-9057-7E499E89B8FC
P2860
Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bapineuzumab and solanezumab f ...... scade hypothesis' still alive?
@en
type
label
Bapineuzumab and solanezumab f ...... scade hypothesis' still alive?
@en
prefLabel
Bapineuzumab and solanezumab f ...... scade hypothesis' still alive?
@en
P2093
P2860
P1476
Bapineuzumab and solanezumab f ...... scade hypothesis' still alive?
@en
P2093
Bruce H Price
Evan D Murray
Frank I Tarazi
Haythum O Tayeb
P2860
P304
P356
10.1517/14712598.2013.789856
P407
P577
2013-04-10T00:00:00Z